Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.66 |
| ▸ | CA2 | P00918 | 9/20 | 0.58 |
| ▸ | CA1 | P00915 | 8/20 | 0.58 |
| ▸ | ACHE | P22303 | 6/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6560885 | 0.90 | PTGS2 (0.66) | PTGS2PTGS1CA2CA1ACHE | |
| SCHEMBL5856588 | 0.89 | PTGS1 (0.72) | PTGS2PTGS1 | |
| SCHEMBL5856299 | 0.84 | L3MBTL1 (0.71) | PTGS2PTGS1CA2CA1L3MBTL1 | |
| SCHEMBL5856418 | 0.83 | PTGS2 (0.69) | PTGS2PTGS1CA2CA1L3MBTL1 | |
| SCHEMBL5857487 | 0.81 | PTGS1 (0.70) | PTGS2PTGS1CA2CA1L3MBTL1 | |
| SCHEMBL5856358 | 0.81 | PTGS1 (0.73) | PTGS2PTGS1CA2CA1ACHE | |
| SCHEMBL6230657 | 0.80 | CA2 (0.71) | PTGS2PTGS1CA2CA1ACHE | |
| SCHEMBL5858805 | 0.80 | PTGS1 (0.60) | PTGS2PTGS1CA2CA1ACHE | |
| SCHEMBL5857443 | 0.80 | CA2 (0.64) | PTGS2PTGS1CA2CA1ACHE | |
| SCHEMBL5693292 | 0.80 | PTGS2 (0.71) | PTGS2PTGS1CA2CA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516621-A2 | Use of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of cell proliferation diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-03-23 | — | — | EP | claimed |
| EP-1083171-B1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2004-04-28 | — | — | EP | claimed |
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-02-19 | — | — | US | claimed |
| EP-1384477-A1 | UTILIZATION OF PYRAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF PROLIFERATIVE CELL DISEASES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-01-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | VHL, MET, PRMT1 | PTGS2 3894/4885PTGS1 1996/4885CA2 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.